RxDoctor Payments Data

Bilal Murad, MD

Interventional Cardiology · Saint Paul, MNNPI 1922066901

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 22.8%.

$16,817in general payments, 2019–2025

Across 147 payments — averaging $114.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Edwards Lifesciences$4K
  • Abbott$3K
  • Shockwave Medical, Inc$2K
  • Siemens Medical Solutions USA, Inc.$1K
  • Corindus Inc.$1K
  • plus $2K from 9 others
$445,915in research payments, 2019–2025

Across 53 payments — averaging $8413.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$446K

What the payments were for

  • Consulting fees$2,81317%
  • Speaking & faculty fees$1,80011%
  • Travel & lodging$5,25131%
  • Food & beverage$6,95441%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,817 in reported general payments places this provider in the 70th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$135,595
Medicare patients
268
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$147,089
Repatha SureclickEvolocumab132$134,173
XareltoRivaroxaban71$90,787
JardianceEmpagliflozin80$81,147
Praluent PenAlirocumab23$20,655
Metoprolol Succinate402$7,209
ClopidogrelClopidogrel Bisulfate376$5,675
Atorvastatin Calcium253$3,119
Rosuvastatin Calcium216$3,101
Ranolazine ErRanolazine17$2,936
Isosorbide Mononitrate ErIsosorbide Mononitrate103$2,436
Ezetimibe70$1,652
Diltiazem 12hr ErDiltiazem Hcl11$1,610
Losartan Potassium139$1,502
Prasugrel Hcl18$1,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$147,089130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 84 interventional cardiology providers in Minnesota.

Other interventional cardiology in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →